H. Lundbeck A/S
Overview
H. Lundbeck A/S, the company, commonly called Lundbeck, could also be a Danish international pharmaceutical company engaged within the research and development, production, marketing, and sale of drugs for the treatment of disorders within the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, and Parkinsonism.

Headquartered is located in Copenhagen, Denmark; Lundbeck has international production facilities in Denmark, Italy, France, and affiliates or sales offices in more than 50 countries. Lundbeck has several employees, around 5,000 people globally (as of 2017). Thus the company’s products are registered in additional than 100 countries worldwide.

In 2017, the company’s revenue was DKK 17.2 billion (€2.3 billion).

Lundbeck was among the Copenhagen stock exchange (CSE).

Lundbeck was a full member of the committee EU Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

The company ha inaugurated by Hans Lundbeck in 1915 and was initially a trading company supplying a selection of products to the Danish market. This also includes manufacturing, aluminum foil, artificial sweeteners, and equipment.
History
H. Lundbeck A/S established his pharmaceutical market in 1924, importing medicines and cosmetics from companies based in other European and American countries. At the end of the late 1930s, Lundbeck started to provide its medicinal products and had established its research department. Although it had been limited because of a scarcity of raw materials, production continued during the Second war.

When the war ended, Lundbeck continued to grow, and in 1957 the company introduced Truxal (chlorprothixene) for the treatment of schizophrenia, entering the marketplace for brain disorders. In 1954, the Lundbeck Foundation was established to require care of and expand Lundbeck Group’s activities. Also, to provide funding for scientific research of the absolute best quality. Starting from the late 1970s and up through the 1980s, Lundbeck diverted its old agency business. Thus became an obsessive pharmaceutical company that concentrates on the assembly of drugs used to treat the central nervous system’s diseases and disorders. In 1989, Lundbeck founded the drug for antidepressant named Celexa (citalopram), which became the cornerstone for the company’s international expansion, and in 2009 Lundbeck, bought Ovation and established an ad platform within the USA.

In 2012, to specialize in newer, strategic CNS products, Lundbeck sold a portfolio of non-core products to Recordati S.p.A. (Recordati Rare Diseases). In 2014 Lundbeck attained Chelsea Therapeutics for up to $658 million.

In March 2018, the company attained Prexton Therapeutics for up to €905 million ($1.1 billion)

In June 2018, the earlier Millennium Pharmaceuticals CEO, Deborah Dunsire, was selected as the new CEO of Lundbeck.

In September 2019, Lundbeck announced it’d acquire Alder BioPharmaceuticals $18 per share, valuing Alder at almost $2 billion.